Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy

被引:1
|
作者
Kaszubski, Jonatan [1 ]
Gagat, Maciej [2 ,3 ]
Grzanka, Alina [2 ]
Wawrzyniak, Agata [4 ]
Niklinska, Wieslawa [5 ]
Lapot, Magdalena [3 ]
Zuryn, Agnieszka [2 ]
机构
[1] Nicolaus Copernicus Univ Torun, Fac Med, Dept Histol & Embryol, Coll Medicum Bydgoszcz,Vasc Biol Student Res Club, PL-85067 Bydgoszcz, Poland
[2] Nicolaus Copernicus Univ Torun, Fac Med, Dept Histol & Embryol, Coll Med Bydgoszcz, PL-85067 Bydgoszcz, Poland
[3] Mazovian Acad Plock, Fac Med, Coll Med, PL-09402 Plock, Poland
[4] Univ Rzeszow, Inst Med Sci, Coll Med Sci, Dept Histol & Embryol, PL-35310 Rzeszow, Poland
[5] Med Univ Bialystok, Dept Histol & Embryol, PL-15269 Bialystok, Poland
来源
MOLECULES | 2024年 / 29卷 / 22期
关键词
melanoma; rare subtypes of melanoma; mucosal melanoma; uveal melanoma; acral melanoma; cyclin-dependent kinases (CDKs); CDK inhibitors (CDKIs); CDK4/6; CDK7/9; CDK2; ACRAL MELANOMA; UVEAL MELANOMA; DESMOPLASTIC MELANOMA; GENETIC ABERRATIONS; P16; EXPRESSION; MAPK PATHWAY; DISTINCT; CANCER; COMBINATION; PROTEINS;
D O I
10.3390/molecules29225239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential to discover new strategies for treating rare forms of melanoma. In recent years, interest in applying CDK inhibitors (CDKIs) in cancer therapy has grown, as they are able to arrest the cell cycle and inhibit cell proliferation. Current studies highlight selective CDK4/6 inhibitors, like palbociclib or abemaciclib, as a very promising therapeutic option, since they were accepted by the FDA for advanced breast cancer treatment. However, cells of every subtype of melanoma do not react to CDKIs the same way, which is partly because of the genetic differences between them. Herein, we discuss the past and current research relevant to targeting various CDKs in mucosal, uveal and acral melanomas. We also briefly describe the issue of amelanotic and desmoplastic types of melanoma and the need to do more research to discover cell cycle dysregulations, which cause the growth of the mentioned forms of cancer.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Cyclin-dependent kinase inhibitors and angiogenesis in sinonasal carcinomas
    Bottini, Consuelo
    Rossi, Valentina
    Valente, Guido
    Tessitore, Luciana
    CANCER RESEARCH, 2006, 66 (08)
  • [42] Novel potent pharmacological cyclin-dependent kinase inhibitors
    Wesierska-Gadek, Jozefa
    Chamrad, Ivo
    Krystof, Vladimir
    FUTURE MEDICINAL CHEMISTRY, 2009, 1 (09) : 1561 - 1581
  • [43] Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
    Giannone, Gaia
    Tuninetti, Valentina
    Ghisoni, Eleonora
    Genta, Sofia
    Scotto, Giulia
    Mittica, Gloria
    Valabrega, Giorgio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [44] Cyclin-dependent kinase inhibitors move into Phase III
    Malini Guha
    Nature Reviews Drug Discovery, 2012, 11 : 892 - 894
  • [45] Cyclin-dependent kinase inhibitors closer to market launch?
    Galons, Herve
    Oumata, Nassima
    Gloulou, Olfa
    Meijer, Laurent
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (08) : 945 - 963
  • [46] Expression of cyclin-dependent kinase inhibitors in vascular disease
    Tanner, FC
    Yang, ZY
    Duckers, E
    Gordon, D
    Nabel, GJ
    Nabel, EG
    CIRCULATION RESEARCH, 1998, 82 (03) : 396 - 403
  • [47] Functional analysis of cyclin-dependent kinase inhibitors of Arabidopsis
    De Veylder, L
    Beeckman, T
    Beemster, GTS
    Krols, L
    Terras, P
    Landrieu, I
    Van der Schueren, E
    Maes, S
    Naudts, M
    Inzé, D
    PLANT CELL, 2001, 13 (07): : 1653 - 1667
  • [48] ROLE OF THE CYCLIN-DEPENDENT KINASE INHIBITORS IN THE DEVELOPMENT OF CANCER
    HIRAMA, T
    KOEFFLER, HP
    BLOOD, 1995, 86 (03) : 841 - 854
  • [49] Cyclin-dependent kinase inhibitors: novel anticancer agents
    Mani, S
    Wang, CG
    Wu, KM
    Francis, R
    Pestell, R
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (08) : 1849 - 1870
  • [50] Cyclin-dependent kinase inhibitors move into Phase III
    Guha, Malini
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (12) : 892 - 894